Stabilization of protein-protein interactions in drug discovery

ABSTRACT Introduction: PPIs are involved in every disease and specific modulation of these PPIs with small molecules would significantly improve our prospects of developing therapeutic agents. Both industry and academia have engaged in the identification and use of PPI inhibitors. However in comparison, the opposite strategy of employing small-molecule stabilizers of PPIs is underrepresented in drug discovery. Areas covered: PPI stabilization has not been exploited in a systematic manner. Rather, this concept validated by a number of therapeutically used natural products like rapamycin and paclitaxel has been shown retrospectively to be the basis of the activity of synthetic molecules originating from drug discovery projects among them lenalidomide and tafamidis. Here, the authors cover the growing number of synthetic small-molecule PPI stabilizers to advocate for a stronger consideration of this as a drug discovery approach. Expert opinion: Both the natural products and the growing number of synthetic molecules show that PPI stabilization is a viable strategy for drug discovery. There is certainly a significant challenge to adapt compound libraries, screening techniques and downstream methodologies to identify, characterize and optimize PPI stabilizers, but the examples of molecules reviewed here in our opinion justify these efforts.

[1]  A. Dulak,et al.  Potent and selective bivalent inhibitors of BET bromodomains. , 2016, Nature chemical biology.

[2]  Chin-Chun Lu,et al.  A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase , 2016, Nature.

[3]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[4]  Timothy Grant,et al.  Activation of NMDA receptors and the mechanism of inhibition by ifenprodil , 2016, Nature.

[5]  G. Petzold,et al.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.

[6]  Salvador Ventura,et al.  Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity , 2016, Nature Communications.

[7]  Morkos A. Henen,et al.  Stabilizer-Guided Inhibition of Protein-Protein Interactions. , 2015, Angewandte Chemie.

[8]  C. Ottmann,et al.  Stabilization of Protein-Protein Interactions in chemical biology and drug discovery. , 2015, Progress in biophysics and molecular biology.

[9]  C. Buscaglia,et al.  Inhibition by stabilization: targeting the Plasmodium falciparum aldolase–TRAP complex , 2015, Malaria Journal.

[10]  D. Kihara,et al.  Structure and inhibition of EV-D68, a virus that causes respiratory illness in children , 2015, Science.

[11]  Fabrizio Giordanetto,et al.  Stabilization of protein-protein interactions by small molecules. , 2014, Drug discovery today.

[12]  Zhe Zhang,et al.  Rational Design of Small-Molecule Stabilizers of Spermine Synthase Dimer by Virtual Screening and Free Energy-Based Approach , 2014, PloS one.

[13]  Brandon M. Brown,et al.  New Positive Ca2+-Activated K+ Channel Gating Modulators with Selectivity for KCa3.1 , 2014, Molecular Pharmacology.

[14]  Hiro Furukawa,et al.  Crystal structure of a heterotetrameric NMDA receptor ion channel , 2014, Science.

[15]  C. Ottmann,et al.  Modulators of protein-protein interactions. , 2014, Chemical reviews.

[16]  Mike Tyers,et al.  E2 enzyme inhibition by stabilization of a low affinity interface with ubiquitin , 2013, Nature chemical biology.

[17]  Kristian Helin,et al.  Chromatin proteins and modifications as drug targets , 2013, Nature.

[18]  M. Štěrba,et al.  Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells , 2013, PloS one.

[19]  Wolfgang Weninger,et al.  A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. , 2013, Cancer research.

[20]  W. Zwart,et al.  Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface , 2013, Proceedings of the National Academy of Sciences.

[21]  Svetlana V. Antonyuk,et al.  Ligand binding and aggregation of pathogenic SOD1 , 2013, Nature Communications.

[22]  C. Ottmann,et al.  A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface. , 2013, Chemistry & biology.

[23]  J. Pascal,et al.  Unstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+-sensing and SK channel activation , 2013, Proceedings of the National Academy of Sciences.

[24]  R. Young,et al.  Transcriptional Regulation and Its Misregulation in Disease , 2013, Cell.

[25]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[26]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[27]  C. Ottmann,et al.  An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction. , 2012, Chemistry.

[28]  S. Rizzo,et al.  Selective chemical imaging of static actin in live cells. , 2012, Journal of the American Chemical Society.

[29]  R. McGuire,et al.  X-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11β-Substituted Steroids , 2012, The Journal of Biological Chemistry.

[30]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[31]  R. Armen,et al.  Identification of the functional binding pocket for compounds targeting small-conductance Ca2+-activated potassium channels , 2012, Nature Communications.

[32]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[33]  R. Geahlen,et al.  Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity. , 2011, Chemistry & biology.

[34]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[35]  Eric T Baldwin,et al.  Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers , 2011, Proceedings of the National Academy of Sciences.

[36]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[37]  Mike Tyers,et al.  An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme , 2011, Cell.

[38]  Hiro Furukawa,et al.  Subunit Arrangement and Phenylethanolamine Binding in GluN1/GluN2B NMDA Receptors , 2011, Nature.

[39]  Roberto Dominguez,et al.  Actin structure and function. , 2011, Annual review of biophysics.

[40]  C. Robinson,et al.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation , 2010, Proceedings of the National Academy of Sciences.

[41]  J. Kubanek,et al.  Two molecules of lobophorolide cooperate to stabilize an actin dimer using both their "ring" and "tail" region. , 2010, Chemistry & biology.

[42]  H. Gronemeyer,et al.  A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor , 2010, Nature Structural &Molecular Biology.

[43]  C. Ottmann,et al.  Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. , 2010, Angewandte Chemie.

[44]  B. Chazotte Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging. , 2010, Cold Spring Harbor protocols.

[45]  David J Weber,et al.  Phenothiazines inhibit S100A4 function by inducing protein oligomerization , 2010, Proceedings of the National Academy of Sciences.

[46]  Peter T Lansbury,et al.  Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. , 2010, Journal of medicinal chemistry.

[47]  Peter W. Collingridge,et al.  Moonlighting enzymes in parasitic protozoa , 2010, Parasitology.

[48]  Steven M. Johnson,et al.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. , 2010, Journal of the American Chemical Society.

[49]  Steven M. Johnson,et al.  Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. , 2010, Current opinion in structural biology.

[50]  A. Fersht,et al.  Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.

[51]  T. Pollard,et al.  Characterization of two classes of small molecule inhibitors of Arp2/3 complex , 2009, Nature.

[52]  H. Gronemeyer,et al.  Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. , 2009, Chemistry & biology.

[53]  Gregor Hagelueken,et al.  The absolute configuration of rhizopodin and its inhibition of actin polymerization by dimerization. , 2009, Angewandte Chemie.

[54]  M. Štěrba,et al.  Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.

[55]  E. Medcalf,et al.  Studies of an Influenza A Virus Temperature-Sensitive Mutant Identify a Late Role for NP in the Formation of Infectious Virions , 2008, Journal of Virology.

[56]  Steven M. Johnson,et al.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. , 2008, Journal of medicinal chemistry.

[57]  M. Grigorian,et al.  Metastasis-inducing S100A4 protein: implication in non-malignant human pathologies. , 2008, Current molecular medicine.

[58]  S. Renner,et al.  Total synthesis of chondramide C and its binding mode to F-actin. , 2008, Angewandte Chemie.

[59]  U. Eggert,et al.  Chondramide C: synthesis, configurational assignment, and structure-activity relationship studies. , 2008, Angewandte Chemie.

[60]  Narine Sarvazyan,et al.  Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[62]  J. Kelly,et al.  Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. , 2008, Biochemistry.

[63]  J. L. Hansen,et al.  S100A4: a common mediator of epithelial–mesenchymal transition, fibrosis and regeneration in diseases? , 2008, Journal of molecular medicine.

[64]  N. Murgolo,et al.  KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? , 2008, Expert review of molecular diagnostics.

[65]  Steven M. Johnson,et al.  Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. , 2008, Journal of medicinal chemistry.

[66]  K. Hahn,et al.  A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamics. , 2008, Biochemistry.

[67]  T. Liljefors,et al.  Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. , 2007, Chemistry & biology.

[68]  I. Rayment,et al.  A structural basis for regulation of actin polymerization by pectenotoxins. , 2007, Journal of molecular biology.

[69]  Gerhard Klebe,et al.  Strategies to search and design stabilizers of protein–protein interactions: A feasibility study , 2007, Proteins.

[70]  Shawn P Williams,et al.  A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. , 2007, Molecular endocrinology.

[71]  Timothy M Willson,et al.  X-ray Crystal Structures of the Estrogen-related Receptor-γ Ligand Binding Domain in Three Functional States Reveal the Molecular Basis of Small Molecule Regulation* , 2006, Journal of Biological Chemistry.

[72]  G. Eichele,et al.  International Union of Pharmacology. LX. Retinoic Acid Receptors , 2006, Pharmacological Reviews.

[73]  Vincent Laudet,et al.  Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.

[74]  Matthew D. Welch,et al.  The ARP2/3 complex: an actin nucleator comes of age , 2006, Nature Reviews Molecular Cell Biology.

[75]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[76]  N. Chirgadze,et al.  A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[77]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[78]  David J Weber,et al.  S100A4, a Mediator of Metastasis* , 2006, Journal of Biological Chemistry.

[79]  Joshua T Dudman,et al.  Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors , 2005, The Journal of Neuroscience.

[80]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[81]  Michael G. Rosenfeld,et al.  Controlling nuclear receptors: the circular logic of cofactor cycles , 2005, Nature Reviews Molecular Cell Biology.

[82]  R. Falk,et al.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.

[83]  K. Namba,et al.  Position and orientation of phalloidin in F-actin determined by X-ray fiber diffraction analysis. , 2005, Biophysical journal.

[84]  Peter T Lansbury,et al.  Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Roderick E Hubbard,et al.  Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Ivan Rayment,et al.  Structural basis of swinholide A binding to actin. , 2005, Chemistry & biology.

[87]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[88]  Sohaib A. Khan,et al.  A two-site model for antiestrogen action , 2004, Mechanisms of Ageing and Development.

[89]  C. Heizmann,et al.  S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). , 2004, Biochemical and biophysical research communications.

[90]  Ralf Flaig,et al.  Structural Basis for the Deactivation of the Estrogen-related Receptor γ by Diethylstilbestrol or 4-Hydroxytamoxifen and Determinants of Selectivity* , 2004, Journal of Biological Chemistry.

[91]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[92]  J. Rao,et al.  Microfilament actin remodeling as a potential target for cancer drug development. , 2004, Current cancer drug targets.

[93]  J. Kelly,et al.  Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants , 2004, Laboratory Investigation.

[94]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[95]  James C Sacchettini,et al.  Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.

[96]  I. Rayment,et al.  Biomolecular mimicry in the actin cytoskeleton: Mechanisms underlying the cytotoxicity of kabiramide C and related macrolides , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[97]  J. Sacchettini,et al.  Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. , 2003, Journal of the American Chemical Society.

[98]  J. Berger,et al.  Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  J. Sacchettini,et al.  Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. , 2003, Angewandte Chemie.

[100]  M. C. Sullards,et al.  Seaweed resistance to microbial attack: A targeted chemical defense against marine fungi , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. Bates,et al.  Dolastatin 11 connects two long-pitch strands in F-actin to stabilize microfilaments. , 2003, Journal of molecular biology.

[102]  J. Scuvée-Moreau,et al.  Modulation of small conductance calcium-activated potassium (SK) channels: a new challenge in medicinal chemistry. , 2003, Current medicinal chemistry.

[103]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[104]  I. Coppens,et al.  Myosin A tail domain interacting protein (MTIP) localizes to the inner membrane complex of Plasmodium sporozoites , 2003, Journal of Cell Science.

[105]  Arun K. Ghosh,et al.  (−)-Doliculide, a New Macrocyclic Depsipeptide Enhancer of Actin Assembly* , 2002, The Journal of Biological Chemistry.

[106]  M. Mayer,et al.  Mechanism of glutamate receptor desensitization , 2002, Nature.

[107]  T. Hsieh,et al.  ATPase Domain of Eukaryotic DNA Topoisomerase II , 2002, The Journal of Biological Chemistry.

[108]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[109]  J. Kelly,et al.  Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. , 2002, Journal of medicinal chemistry.

[110]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[111]  J. Lehmann,et al.  4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  E. Sausville,et al.  Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. , 2001, Molecular pharmacology.

[113]  P. Ornstein,et al.  Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic acid (AMPA) receptors. , 2000, Journal of medicinal chemistry.

[114]  E. Gouaux,et al.  Mechanisms for Activation and Antagonism of an AMPA-Sensitive Glutamate Receptor Crystal Structures of the GluR2 Ligand Binding Core , 2000, Neuron.

[115]  K. Chwalisz,et al.  Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity , 2000, Steroids.

[116]  J. Gustafsson,et al.  Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. , 2000, Biochemical and biophysical research communications.

[117]  James C. Sacchettini,et al.  Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.

[118]  H. M. Petrassi,et al.  Structure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors , 2000 .

[119]  I. Spector,et al.  Effects of Jasplakinolide on the Kinetics of Actin Polymerization , 2000, The Journal of Biological Chemistry.

[120]  Scott A. Peterson,et al.  Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. , 1999, Bioorganic & medicinal chemistry.

[121]  J. Kelly,et al.  Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[122]  H. Reichenbach,et al.  The chondramides: cytostatic agents from myxobacteria acting on the actin cytoskeleton. , 1998, Journal of the National Cancer Institute.

[123]  Scott A. Peterson,et al.  Discovering transthyretin amyloid fibril inhibitors by limited screening. , 1998, Bioorganic & medicinal chemistry.

[124]  U Aebi,et al.  Evaluating atomic models of F-actin with an undecagold-tagged phalloidin derivative. , 1998, Journal of molecular biology.

[125]  V. Ferrans,et al.  Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. , 1998, Current medicinal chemistry.

[126]  M. Piotrowski,et al.  Topology and target interaction of the fusicoccin‐binding 14‐3‐3 homologs of Commelina communis , 1997 .

[127]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[128]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[129]  A. K. Singh,et al.  Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca(2+)-dependent K+ channel. , 1996, The American journal of physiology.

[130]  D. Zimmer,et al.  The S100 protein family: History, function, and expression , 1995, Brain Research Bulletin.

[131]  V. Müller,et al.  A New Interpretation of Antiestrogen Action a , 1995, Annals of the New York Academy of Sciences.

[132]  Robert H. Brown,et al.  Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice , 1995, Cell.

[133]  A. Bershadsky,et al.  Swinholide A Is a Microfilament Disrupting Marine Toxin That Stabilizes Actin Dimers and Severs Actin Filaments (*) , 1995, The Journal of Biological Chemistry.

[134]  M G Rossmann,et al.  Viral cell recognition and entry. , 1994, Protein science : a publication of the Protein Society.

[135]  E. Sausville,et al.  Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. , 1994, The Journal of biological chemistry.

[136]  J. Wang,et al.  Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[137]  S. Olesen,et al.  Selective activation of Ca(2+)-dependent K+ channels by novel benzimidazolone. , 1994, European journal of pharmacology.

[138]  H. Reichenbach,et al.  Rhizopodin, a new compound from Myxococcus stipitatus (myxobacteria) causes formation of rhizopodia-like structures in animal cell cultures. Production, isolation, physico-chemical and biological properties. , 1993, The Journal of antibiotics.

[139]  T. Andoh,et al.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. , 1991, Cancer research.

[140]  E. Kuechler,et al.  Stabilization of human rhinovirus serotype 2 against pH-induced conformational change by antiviral compounds. , 1991, The Journal of general virology.

[141]  J. Tanaka,et al.  Marine natural products. XXIII. Three new cytotoxic dimeric macrolides, swinholides B and C and isoswinholide A, congeners of swinholide A, from the Okinawan marine sponge Theonella swinhoei. , 1990, Chemical & pharmaceutical bulletin.

[142]  D. Duverger,et al.  Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. , 1988, The Journal of pharmacology and experimental therapeutics.

[143]  G Vriend,et al.  The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. , 1986, Science.

[144]  M. Otto,et al.  Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug , 1986, Antimicrobial Agents and Chemotherapy.

[145]  M. Mckinlay,et al.  Isoxazoles with antipicornavirus activity. , 1985, Journal of medicinal chemistry.

[146]  V. Jordan,et al.  Geometric isomers of substituted triphenylethylenes and antiestrogen action. , 1981, Endocrinology.

[147]  K. Weber,et al.  Phalloidin-induced actin polymerization in the cytoplasm of cultured cells interferes with cell locomotion and growth. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[148]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[149]  T. Wieland Modification of actins by phallotoxins , 1977, Naturwissenschaften.

[150]  K.,et al.  A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.

[151]  Olivier Sperandio,et al.  Stabilization of protein-protein interaction complexes through small molecules. , 2016, Drug discovery today.

[152]  Laurent Blanchoin,et al.  Actin dynamics, architecture, and mechanics in cell motility. , 2014, Physiological reviews.

[153]  C. Buscaglia,et al.  Plasmodium sporozoite motility: an update. , 2012, Frontiers in bioscience.

[154]  J. Stehn,et al.  Therapeutic Targeting of the Actin Cytoskeleton in Cancer , 2012 .

[155]  H. Reichenbach,et al.  Effects of rhizopodin and latrunculin B on the morphology and on the actin cytoskeleton of mammalian cells , 1999, Cell and Tissue Research.

[156]  G. Schmidt,et al.  Über die Giftstoffe des Knollenblätterpilzes VIII , 1938 .